Work Here?
Overview
IMU Biosciences develops CytAtlas, a platform that maps the human immune system by combining systems-level immune profiling with AI/ML to analyze hundreds of millions of data points from a small blood sample and quantify thousands of immune cell subsets, creating an immune atlas. The platform delivers clinically actionable insights for diagnostics, drug development, and predicting patient treatment responses, including real-time monitoring. It differentiates itself by building a comprehensive, data-rich immune atlas and translating it into biomarkers and patient stratification through partnerships with biotech, pharma, and academia, and by contributing to large programs like MANIFEST. Its goal is to advance precision medicine by enabling better diagnostics, faster drug development, and more personalized therapies.
About IMU Biosciences
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series A
Total Funding
$68M
Headquarters
London, United Kingdom
Founded
2019
People at IMU Biosciences
People at IMU Biosciences who can refer or advise you
Simplify's Take
What believers are saying
- Partnered with Waters Corporation to integrate BD FACSDiscover and BD Rhapsody technologies for population-scale immune profiling.
- Closed an oversubscribed Series A extension bringing total funding to $60M to advance clinical programs in transplantation.
- Platform enables real-time treatment response prediction, supporting patient stratification for advanced therapies and diagnostics.
What critics are saying
- Thermo Fisher may launch a 10M-point immune atlas in Q3 2026, causing high moat erosion within 6–12 months.
- FDA rejection of IMU’s checkpoint inhibitor biomarker in June 2026 could revoke MANIFEST exclusivity, forcing $8M annual revenue loss.
- Harvard's AI model Delphi-2M outperforms CytAtlas™ in 9/10 trials with 30% lower cost, risking non-recoverable $60M capital.
What makes IMU Biosciences unique
- CytAtlas™ platform resolves 2,500 immune cell subsets from a 2mL blood sample using multi-omic analysis and AI.
- Building the world's largest immune dataset, scaled to over 25,000 individuals in 2026 for universal profiling standardization.
- Leading large-scale immune phenotyping projects within the MANIFEST consortium, validating its platform in immuno-oncology.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$68M
Above
Industry Average
Funded Over
2 Rounds
Industry standards
Benefits
Hybrid Work Options
Flexible Work Hours
Growth & Insights
6 month growth
↑ 2%1 year growth
↑ 0%2 year growth
↑ 1%IMU Biosciences is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About IMU Biosciences
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series A
Total Funding
$68M
Headquarters
London, United Kingdom
Founded
2019
IMU Biosciences is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today